ReviewMaterials today. Bio2026
Emerging roles of microfluidics in oral cancer research and clinical translation.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral cancer remains a global health burden, with limited improvements in long-term survival despite advances in multimodal therapy. Advances in early diagnosis and treatment strategies for oral cancer patients will significantly improve survival outcomes. Microfluidic technology, with its capacity for precise fluid manipulation, high-throughput analysis, and experimental miniaturization, has emerged as a powerful tool to accelerate innovations in cancer research and has become a pivotal pathway in oral cancer investigation and clinical translation. This review systematically examines the expanding roles of microfluidics in oral cancer research, with a particular focus on microfluidics-based liquid biopsy for early detection and prognosis, and microfluidics-enabled therapeutic strategies for treatment development and optimization. By bridging basic research with clinical application, microfluidics holds the potential to revolutionize early diagnosis, precision therapeutics, and functional outcome-oriented management in oral cancer, ultimately improving patient survival and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.